Sodium Hydroxide → 5-(1'-{[3,5-Diethoxy-4-(1-methyl-1h-pyrazol-4-yl)phenyl]carbonyl}-4-oxospiro[chroman-2,4'-piperidin]-6-yl)pyridine-3-carboxylic acid sodium salt

Participants

Reaction Steps

5-(1′-{[3,5-Diethoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl]carbonyl}-4-oxospiro[chroman-2,4′-piperidin]-6-yl)pyridine-3-carboxylic acid (285 mg) was suspended in water (6 mL), and aqueous 1 N sodium hydroxide solution (0.624 mL) was added to it at room temperature, and stirred for 1 hour. The reaction liquid was purified through ODS reversed-phase chromatography (water/methanol) to obtain the title compound. 1H-NMR (400 MHz, DMSO-d6) δ: 8.90-8.87 (1.0H, m), 8.74-8.72 (1.0H, m), 8.28-8.26 (1.0H, m), 8.05 (1.0H, s), 7.99-7.95 (2.0H, m), 7.93-7.92 (1.0H, m), 7.22 (1.0H, d, J=9.3 Hz), 6.69 (2.0H, s), 4.35-4.18 (1.0H, br m), 4.08 (4.0H, q, J=6.8 Hz), 3.86 (3.0H, s), 3.69-3.17 (3.0H, m), 2.93 (2.0H, s), 2.15-1.86 (2.0H, m), 1.85-1.74 (2.0H, m), 1.38 (6.0H, t, J=7.0 Hz). MS [M+Na]+=633.

Provenance & Evidence